Mapping the time-dependent effects of paricalcitol on serum calcium, phosphorus and parathyroid hormone levels in 5/6 nephrectomized uremic rats

被引:4
作者
Wu-Wong, J. Ruth [1 ]
Nakane, Masaki [2 ]
Chen, Yung-wu [2 ]
机构
[1] Univ Illinois, Dept Pharm Practice, Chicago, IL 60612 USA
[2] VidaGene, Chicago, IL USA
关键词
Chronic kidney disease; Paricalcitol; Hypercalcemia; PTH; CHRONIC KIDNEY-DISEASE; SPONTANEOUSLY HYPERTENSIVE-RAT; RANDOMIZED CONTROLLED-TRIAL; D-RECEPTOR ACTIVATION; VITAMIN-D ANALOGS; SECONDARY HYPERPARATHYROIDISM; HEMODIALYSIS-PATIENTS; RENAL-INSUFFICIENCY; IMPROVED SURVIVAL; ORAL CALCITRIOL;
D O I
10.1016/j.lfs.2012.11.018
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Aims: To investigate whether the frequency of monitoring paricalcitol's impact on serum calcium (Ca), phosphorus and PTH in current clinical practice is sufficient by mapping the time-dependent effects of paricalcitol on these parameters. Main methods: The 5/6 nephrectomized (NX) male, Sprague-Dawley rats with established uremia were treated with vehicle or paricalcitol (0.16 mu g/kg, i.p., 3 X/week). On Day 0 (before treatment), Days 12 and 13 after treatment, and also at 0, 1, 4, 8, 16, 24 h after the last dosing, blood and small intestine samples were collected. Key findings: Serum creatinine and blood urea nitrogen levels were significantly elevated in 5/6 NX rats. Significant increases were observed in serum Ca while PTH decreased by >90% when the parameters were determined at 12 or 13 days after paricalcitol dosing. Paricalcitol caused a step-wise increase in serum Ca levels at 1-24 h following dosing, reduced serum PTH levels with PTH values ranging from 1.06 +/- 0.06 to 26.7 +/- 25.7 pg/ml (vs. 152 +/- 15 pg/ml in Sham rats), but did not affect serum phosphorus in a time-dependent manner. Consistent with the serum Ca data, paricalcitol significantly induced the intestinal expression of Calb3 and TRPV6, genes involved in intestinal Ca transport, and also significantly induced the intestirial calcium absorption. Significance: Our results suggest that the frequency of monitoring paricalcitol's effect on serum Ca, phosphorus and PTH in current clinical practice seems adequate. Additional clinical trials may be needed to resolve the inconsistent clinical observations about the impact of paricalcitol on serum Ca. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:161 / 166
页数:6
相关论文
共 49 条
  • [1] A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4
    Abboud, H
    Coyne, D
    Smolenski, O
    Anger, M
    Lunde, N
    Qiu, P
    Hippensteel, R
    Pradhan, RS
    Palaparthy, RV
    Kavanaugh, A
    Melnick, JZ
    Williams, LA
    Batlle, D
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 2006, 26 (01) : 105 - 114
  • [2] Antiproteinuric effect of oral paricalcitol in chronic kidney disease
    Agarwal, R
    Acharya, M
    Tian, J
    Hippensteel, RL
    Melnick, JZ
    Qiu, P
    Williams, L
    Batlle, D
    [J]. KIDNEY INTERNATIONAL, 2005, 68 (06) : 2823 - 2828
  • [3] Paricalcitol reduces albuminuria and inflammation in chronic kidney disease - A randomized double-blind pilot trial
    Alborzi, Pooneh
    Patel, Nina A.
    Peterson, Carla
    Bills, Jennifer E.
    Bekele, Dagim M.
    Bunaye, Zerihun
    Light, Robert P.
    Agarwal, Rajiv
    [J]. HYPERTENSION, 2008, 52 (02) : 249 - 255
  • [4] Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation
    Andress, DL
    [J]. KIDNEY INTERNATIONAL, 2006, 69 (01) : 33 - 43
  • [5] Vitamin D Affects Survival Independently of Vascular Calcification in Chronic Kidney Disease
    Barreto, Daniela Veit
    Barreto, Fellype Carvalho
    Liabeuf, Sophie
    Temmar, Mohammed
    Boitte, Francis
    Choukroun, Gabriel
    Fournier, Albert
    Massy, Ziad A.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (06): : 1128 - 1135
  • [6] Vitamin D, chronic kidney disease and survival: a pluripotent hormone or just another bone drug?
    Biggar, Patrick H.
    Liangos, Orfeas
    Fey, Holger
    Brandenburg, Vincent M.
    Ketteler, Markus
    [J]. PEDIATRIC NEPHROLOGY, 2011, 26 (01) : 7 - 18
  • [7] Effect of cholecalciferol treatment on the relaxant responses of spontaneously hypertensive rat arteries to acetylcholine
    Borges, ACR
    Feres, T
    Vianna, LM
    Paiva, TB
    [J]. HYPERTENSION, 1999, 34 (04) : 897 - 901
  • [8] AN ANALYSIS OF INTESTINAL CALCIUM-TRANSPORT ACROSS THE RAT INTESTINE
    BRONNER, F
    PANSU, D
    STEIN, WD
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1986, 250 (05): : G561 - G569
  • [9] Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease
    Cheng, S
    Coyne, D
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (05) : 617 - 621
  • [10] The Effects of Vitamin D Therapy on Left Ventricular Structure and Function - Are These the Underlying Explanations for Improved CKD Patient Survival?
    Covic, Adrian
    Voroneanu, Luminita
    Goldsmith, David
    [J]. NEPHRON CLINICAL PRACTICE, 2010, 116 (03): : C187 - C195